"We are delighted to report this highly encouraging progression-free survival data in Met-driven papillary renal cell carcinoma (PRCC), a disease with no approved treatment options," said Christian Hogg, CEO of Hutchison China MediTech Ltd. (Chi-Med). "With development of the companion diagnostic assay to screen Met-driven disease now also complete we are preparing for the initiation of our global Phase III study, the first global registration trial for savolitinib."
The positive Phase II data of savolitinib in PRCC and other savolitinib data are to be presented later this week at the 2017 Genitourinary Cancers Symposium sponsored